World's Best Scientists 2026 revealed!
Award Badge
Medicine
Germany
2026

D-Index & Metrics

Medicine

D-Index
151
Citations
101465
World Ranking
1105
National Ranking
52

Research.com Recognitions

  • 2026 - Research.com Medicine in Germany Leader Award
  • 2023 - Research.com Medicine in Germany Leader Award

Overview

Wolfgang Wick is affiliated with the German Cancer Research Center in Germany. The primary focus of their research lies within the broad field of Medicine, with significant contributions in subfields such as Genetics, Radiology, Nuclear Medicine and Imaging, Molecular Biology, Pulmonary and Respiratory Medicine, and Oncology.

The scientist's work prominently addresses the diagnosis and treatment of gliomas, a major topic within their portfolio, alongside other key areas including brain metastases and treatment, radiomics and machine learning in medical imaging, meningioma and schwannoma management, CAR-T cell therapy research, immunotherapy and immune responses, and cancer genomics and diagnostics.

Wolfgang Wick has published extensively in several academic venues, with a notable number of publications in:

  • Neuro-Oncology
  • Cancer
  • Neuro-Oncology Advances
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Acta Neuropathologica

Their recent scholarly output includes these papers:

  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2020, Nature Reviews Clinical Oncology)
  • How to use and assess qualitative research methods (2020, Neurological Research and Practice)
  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions (2020, Neuro-Oncology)
  • Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022, Annals of Oncology)
  • Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (2023, New England Journal of Medicine)

Collaborative efforts form an integral part of their research, with frequent co-authors including:

  • Felix Sahm
  • Andreas von Deimling
  • Martin Bendszus
  • Michael Weller
  • Michael Platten

Best Publications

  • Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy

  • DNA methylation-based classification of central nervous system tumours

    David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt

  • Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

    Olivier L. Chinot;Wolfgang Wick;Warren Mason;Roger Henriksson

  • Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

    Dominik Sturm;Hendrik Witt;Hendrik Witt;Volker Hovestadt;Dong Anh Khuong-Quang

  • An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

    Christiane A. Opitz;Ulrike M. Litzenburger;Ulrike M. Litzenburger;Felix Sahm;Martina Ott

  • Identifying the Best Machine Learning Algorithms for Brain Tumor Segmentation, Progression Assessment, and Overall Survival Prediction in the BRATS Challenge

    Spyridon Bakas;Mauricio Reyes;Andras Jakab;Stefan Bauer

  • Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

    Christian Hartmann;Christian Hartmann;Jochen Meyer;Jörg Balss;David Capper

  • Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

    Wolfgang Wick;Michael Platten;Christoph Meisner;Joerg Felsberg

  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

    Michael Weller;Martin van den Bent;Matthias Preusser;Emilie Le Rhun

  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

    Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge

  • Brain tumour cells interconnect to a functional and resistant network

    Matthias Osswald;Matthias Osswald;Erik Jung;Erik Jung;Felix Sahm;Felix Sahm;Gergely Solecki;Gergely Solecki

  • Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas

    Christian Hartmann;Christian Hartmann;Bettina Hentschel;Wolfgang Wick;Wolfgang Wick;David Capper

  • Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

    James R. Perry;Normand Laperriere;Christopher J. O'Callaghan;Alba A. Brandes

  • Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

    Simone Fulda;Wolfgang Wick;Michael Weller;Klaus Michael Debatin;Klaus Michael Debatin

  • Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

    Monika E. Hegi;Lili Liu;James G. Herman;Roger Stupp

  • European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

    Michael Weller;Martin van den Bent;Jörg C Tonn;Roger Stupp

  • NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

    Wolfgang Wick;Christian Hartmann;Corinna Engel;Mandy Stoffels

  • Lomustine and Bevacizumab in Progressive Glioblastoma

    Wolfgang Wick;Thierry Gorlia;Martin Bendszus;Martin Taphoorn

  • MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

    Michael Weller;Roger Stupp;Guido Reifenberger;Alba A. Brandes

  • How to use and assess qualitative research methods.

    Loraine Busetto;Wolfgang Wick;Wolfgang Wick;Christoph Gumbinger

Frequent Co-Authors

Michael Weller
Michael Weller University of Zurich
Felix Sahm
Felix Sahm University Hospital Heidelberg
Andreas von Deimling
Andreas von Deimling Heidelberg University
Martin Bendszus
Martin Bendszus University Hospital Heidelberg
Stefan M. Pfister
Stefan M. Pfister German Cancer Research Center
Martin J. van den Bent
Martin J. van den Bent Erasmus University Rotterdam
David Capper
David Capper Charité - University Medicine Berlin
Roger Stupp
Roger Stupp Northwestern University
Guido Reifenberger
Guido Reifenberger Heinrich Heine University Düsseldorf
Sabine Heiland
Sabine Heiland University Hospital Heidelberg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a wide range of healthcare careers that don’t always require traditional paths. For those interested in the administrative side, medical billing and coding schools online provide flexible options and are vital in ensuring healthcare facilities run smoothly.

Those looking to enter the nursing field can benefit from nursing schools that don't require teas, which can help bypass certain exam barriers and streamline the admissions process. If management and leadership are your goals, healthcare administration programs online can help you gain the necessary skills efficiently.

Nurses seeking to advance their qualifications can take advantage of rn to fnp bridge programs designed to fast-track career progression from registered nurse to family nurse practitioner. These alternative pathways reflect the growing flexibility and opportunity within the US healthcare education system, making it easier than ever to find a route that matches your career goals.

Best Scientists Citing Wolfgang Wick

Trending Scientists